These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

232 related items for PubMed ID: 10541115

  • 1. Thymic hyperplasia after high-dose chemotherapy and autologous stem cell transplantation: incidence and significance in patients with breast cancer.
    Hara M, McAdams HP, Vredenburgh JJ, Herndon JE, Patz EF.
    AJR Am J Roentgenol; 1999 Nov; 173(5):1341-4. PubMed ID: 10541115
    [Abstract] [Full Text] [Related]

  • 2. Thymic hyperplasia after adjuvant chemotherapy in breast cancer.
    Sehbai AS, Tallaksen RJ, Bennett J, Abraham J.
    J Thorac Imaging; 2006 Mar; 21(1):43-6. PubMed ID: 16538156
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Conventional adjuvant chemotherapy with or without high-dose chemotherapy and autologous stem-cell transplantation in high-risk breast cancer.
    Tallman MS, Gray R, Robert NJ, LeMaistre CF, Osborne CK, Vaughan WP, Gradishar WJ, Pisansky TM, Fetting J, Paietta E, Lazarus HM.
    N Engl J Med; 2003 Jul 03; 349(1):17-26. PubMed ID: 12840088
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. High-dose chemotherapy with autologous hematopoietic stem-cell support compared with standard-dose chemotherapy in breast cancer patients with 10 or more positive lymph nodes: first results of a randomized trial.
    Zander AR, Kröger N, Schmoor C, Krüger W, Möbus V, Frickhofen N, Metzner B, Schultze W, Berdel WE, Koenigsmann M, Thiel E, Wandt H, Possinger K, Trümper L, Kreienberg R, Carstensen M, Schmidt EH, Jänicke F, Schumacher M, Jonat W.
    J Clin Oncol; 2004 Jun 15; 22(12):2273-83. PubMed ID: 15111618
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Prospective, randomized comparison of high-dose chemotherapy with stem-cell support versus intermediate-dose chemotherapy after surgery and adjuvant chemotherapy in women with high-risk primary breast cancer: a report of CALGB 9082, SWOG 9114, and NCIC MA-13.
    Peters WP, Rosner GL, Vredenburgh JJ, Shpall EJ, Crump M, Richardson PG, Schuster MW, Marks LB, Cirrincione C, Norton L, Henderson IC, Schilsky RL, Hurd DD.
    J Clin Oncol; 2005 Apr 01; 23(10):2191-200. PubMed ID: 15767638
    [Abstract] [Full Text] [Related]

  • 11. Randomized trial of high-dose chemotherapy and autologous hematopoietic stem cell support for high-risk primary breast carcinoma: follow-up at 12 years.
    Hanrahan EO, Broglio K, Frye D, Buzdar AU, Theriault RL, Valero V, Booser DJ, Singletary SE, Strom EA, Gajewski JL, Champlin RE, Hortobagyi GN.
    Cancer; 2006 Jun 01; 106(11):2327-36. PubMed ID: 16639731
    [Abstract] [Full Text] [Related]

  • 12. [Combination of high-dose chemotherapy with autologous hematopoietic stem cell transplantation for recurrent and high-risk breast cancer: a pilot study].
    Shi Y, Pan F, Han X.
    Zhonghua Yi Xue Za Zhi; 1999 Dec 01; 79(12):890-3. PubMed ID: 11715500
    [Abstract] [Full Text] [Related]

  • 13. The significance of tumor contamination in the bone marrow from high-risk primary breast cancer patients treated with high-dose chemotherapy and hematopoietic support.
    Vredenburgh JJ, Silva O, Broadwater G, Berry D, DeSombre K, Tyer C, Petros WP, Peters WP, Bast RC.
    Biol Blood Marrow Transplant; 1997 Jun 01; 3(2):91-7. PubMed ID: 9267669
    [Abstract] [Full Text] [Related]

  • 14. [Thymus hyperplasia in patients with malignant testicular tumors].
    Rüther U, Müller HA, Nunnensiek C, Rupp W, Bader H, Fauser L.
    Med Klin (Munich); 1990 Feb 15; 85(2):72-7. PubMed ID: 2319987
    [Abstract] [Full Text] [Related]

  • 15. A feasibility study of multiple cycle therapy with melphalan, thiotepa, and paclitaxel followed by mitoxantrone, thiotepa, and paclitaxel with autologous hematopoietic cell support for metastatic breast cancer.
    Hu WW, Long GD, Stockerl-Goldstein KE, Johnston LJ, Chao NJ, Negrin RS, Blume KG.
    Clin Cancer Res; 1999 Nov 15; 5(11):3411-8. PubMed ID: 10589752
    [Abstract] [Full Text] [Related]

  • 16. Multicycle dose-intensive chemotherapy for women with high-risk primary breast cancer: results of International Breast Cancer Study Group Trial 15-95.
    International Breast Cancer Study GroupCSL Ltd, 45 Poplar Rd,Parkville, Vic 3052, Australia. russell.basser@csl.com.au, Basser RL, O'Neill A, Martinelli G, Green MD, Peccatori F, Cinieri S, Coates AS, Gelber RD, Aebi S, Castiglione-Gertsch M, Viale G, Price KN, Goldhirsch A.
    J Clin Oncol; 2006 Jan 20; 24(3):370-8. PubMed ID: 16421418
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Conventional adjuvant chemotherapy versus single-cycle, autograft-supported, high-dose, late-intensification chemotherapy in high-risk breast cancer patients: a randomized trial.
    Leonard RC, Lind M, Twelves C, Coleman R, van Belle S, Wilson C, Ledermann J, Kennedy I, Barrett-Lee P, Perren T, Verrill M, Cameron D, Foster E, Yellowlees A, Crown J, Anglo-Celtic Cooperative Oncology Group.
    J Natl Cancer Inst; 2004 Jul 21; 96(14):1076-83. PubMed ID: 15265969
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.